US/UK/Canada

Share

About Us

AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. Our mission is to make the heart stronger safely.

Links

Pick a time period -
Tags ( Active)

AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet

· Favourable safety profile in marked contrast to traditional inotropic therapeutics · AC01 showed rapid and sustained numerical improvements in cardiac output, structure and function STOCKHOLM, Sweden, June 25, 2026 – AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, today announced the publication in The Lancet of results from its Phase 1b/2a GOAL-HF1 study evaluating AC01, a first-in-class, oral calcium-sensitising contractile agent, in patients with heart failure with reduced ejection fraction (HFrEF). The results showed a

AnaCardio Announces Phase 1b/2a GOAL-HF1 Results of AC01 Demonstrating Favorable Safety and Sustained Improvements in Cardiac Function on Top of Standard-of-Care Therapy in HFrEF

STOCKHOLM, Sweden, May 11, 2026 – AnaCardio today announced detailed results from its Phase 1b/2a GOAL-HF1 study evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF), presented in a Late-Breaking Science session at the European Society of Cardiology (ESC) Heart Failure Association (HFA) Congress 2026 in Barcelona, Spain. The randomized, double-blind, placebo-controlled study demonstrated a favorable safety and tolerability profile, dose-proportional pharmacokinetics with confirmed target engagement, and rapid and sustained improvements in hemodynamics and

AnaCardio’s AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 Congress

STOCKHOLM, Sweden – March 26, 2026 – AnaCardio today announces that the results from GOAL-HF1, its Phase 1b/2a study of AC01 in patients with heart failure with reduced ejection fraction (HFrEF) have been selected for presentation in the Late-Breaking Science program at the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) 2026 Congress in Barcelona. Late-Breaking Science presentations are reserved for studies of high scientific and clinical importance, highlighting impactful advances in cardiovascular medicine. The presentation, titled “Randomized, double-

AnaCardio announces issuance of U.S. patent for AC01, strengthening protection into the 2040s

Stockholm, Sweden and Lugano, Switzerland, March 11, 2026 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, today announced that U.S. Patent No. 12,569,476 has been issued by the United States Patent and Trademark Office (USPTO). The patent covers the use of AC01 for the treatment of heart failure with reduced ejection fraction (HFrEF). The patent is co-owned by AnaCardio AB and

AnaCardio Reports Strong Phase 2a Topline Results for AC01 in patients with heart failure and reduced ejection fraction (HFrEF); Paving the Way for Rapid Advancement to Phase 2b

December 10, 2025, Stockholm, Sweden – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents for heart failure, today announces strong topline results from the Phase 2a portion of its GOAL-HF1 clinical study program evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF). AC01 demonstrated a favorable safety and tolerability profile and exploratory efficacy assessments showed encouraging, consistent signals of rapid and sustained improvements in hemodynamics, and cardiac structure and function over 28 days of treatment. These

AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025

Stockholm, Sweden, September 16, 2025 – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents for heart failure, today announced that its ongoing Phase 2a study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF) is fully enrolled and remains on track to report results by year-end 2025. In the Phase 2a part of the GOAL-HF1 study, a total of 26 patients were randomized to receive AC01 or placebo for 28 days at dose levels identified from the previously completed Phase 1b part, which dosed patients over 7 days. The study has been

AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer

Stockholm, Sweden, September 2, 2025 - AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces today the appointment of Philipp Mathieu as Chief Financial Officer (CFO). Philipp is an experienced healthcare executive with two decades of leadership and investment experience across European and US markets. He has successfully led companies, driven healthcare investments, and advised on major strategic transactions across the sector. Most recently, he served as Chief Executive Officer of

AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF

· Alignment reached with both the FDA and EMA on key elements of the AC01 development strategy in chronic HFrEF, allowing for a lean, straightforward and coherent plan across both Europe and the USA · AC01, a novel, selective oral ghrelin receptor (GHSR1a) agonist, is currently in Phase IIa (GOAL-HF1) and the advice will enable the planned Phase IIb study to satisfy both the FDA and EMA recommendationsStockholm, Sweden, July 17, 2025 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announces positive

AnaCardio receives patent grant in Europe for AC01

Stockholm, Sweden and Lugano, Switzerland, March 13, 2025 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, today announced that European patent EP4346820 has been issued by the European Patent Office (EPO), securing the use of AC01/HM01 as an inotropic agent. The patent is co-owned by AnaCardio AB and Helsinn

AnaCardio reports first patient dosed in the phase 2a study evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF)

February 25, 2025, Stockholm, Sweden - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced that the first patient has been dosed in the phase 2a part of the GOAL-HF1 study evaluating AC01 in patients with HFrEF. AC01 is a novel, selective oral ghrelin receptor (GHSR1a) agonist, in development to improve contractility in patients with heart failure. The phase 2a part of the GOAL-HF1 study is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics

AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure

Reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF) · USD 19 million (SEK 205 million) financing round closed with new international investors Novo Holdings, Pureos Bioventures and Sound Bioventures · AC01, a selective oral ghrelin receptor (GHSR1a) agonist was well tolerated in patients with chronic, stable HFrEF · Clear target engagement demonstrated and exploratory pharmacodynamic measurements indicated increased contractilityJanuary 9, 2025, Stockholm, Sweden - AnaCardio, a clinical-stage biopharmaceutical

AnaCardio successfully completes first part of AC01 HFrEF study and provides a clinical update

PRESS RELEASE Stockholm, Sweden, September 17, 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure, today announced that the clinical conduct of the first part of its GOAL-HF1 study in patients with heart failure and reduced ejection fraction (HFrEF) has been completed. Part A of GOAL-HF1 is a randomized, double-blind, placebo-controlled, dose-escalation study (Phase 1b), designed to assess the safety, pharmacokinetic and pharmacodynamic properties of AC01. A total of 32 patients, 8 in each of 4

Michael Grissinger appointed as new Chairman of AnaCardio

PRESS RELEASE Stockholm, Sweden, June 3, 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces today the appointment of Michael Grissinger, B.S M.B.A. as new chairman of the board.Michael has had a long and successful career in the pharmaceutical industry, leading large value business development transactions across multiple therapeutic areas and products. Michael spent more than two decades at Johnson & Johnson, holding positions of Vice President and Head, Worldwide

AnaCardio selected as finalist at the J.P. Morgan Asset Management: Life Sciences Innovation Summit

PRESS RELEASE Stockholm, Sweden, April 4 , 2024AnaCardio, a Swedish clinical-stage biopharmaceutical company focused on developing novel contractile agents to treat patients with heart failure, announced today that it has been selected as one of 11 finalists to present at the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit. The summit will take place on May 14-15, 2024 at the Cleveland Clinic Abu Dhabi during the Abu Dhabi Global Healthcare Week. The aim is to bring together innovators, investors, and industry leaders to explore the latest advancements and trends

AnaCardio receives second tranche of SEK 50 million, completing the previously announced Series A round

PRESS RELEASE Stockholm, Sweden, January 17, 2024AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announced today the closing of the SEK 50 M second tranche of its SEK 150 M Series A financing round. As announced in September 2022, the series A was co-led by Flerie Invest AB (Flerie) and Industrifonden, and where 3B Future Health Fund (3BFHF) joined Flerie and Industrifonden to complete the round together with the founding investor Karolinska Development AB and current investors Fredrik and

AnaCardio receives IND approval from the FDA for AC01 to Start a Clinical Pharmacology Study

PRESS RELEASE Stockholm, Sweden, August 17, 2023AnaCardio, a Swedish clinical-stage biopharmaceutical company focussing on developing novel contractile agents to treat patients with heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for the investigational drug AC01. The approval enables expansion of the clinical development program for AC01 to the US, and to initiate a study in healthy volunteers. This study will evaluate the effects of food on the pharmacokinetics of orally administered

AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK

Solna, Sweden and Lugano, Switzerland, April 13, 2022 - AnaCardio, a Swedish clinical-stage biopharmaceutical company focussed on developing novel contractile agents with a unique mode-of-action based on the ghrelin signaling pathway, today announced that the first patient has been successfully dosed in its GOAL-HF1 study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF). AnaCardio licensed AC01, an oral ghrelin peptidomimetic small-molecule, from Helsinn Group in February 2022.  As previously announced, the GOAL-HF1 study is a Phase 1b/2a multicenter,

Ghrelin treatment in heart failure patients showed increased contractility of the heart

AnaCardio´s founder Prof Lars Lund and colleagues from The Karolinska Institutet publish study on ghrelin treatment in patients with heart failure and in isolated heart cells, demonstrating increased contractility and a novel mechanism of action.AnaCardio, a Swedish clinical-stage biopharmaceutical company focused on developing novel contractile agents with a unique mode-of-action based on the ghrelin signalling pathway, is today reporting on a new publication by researchers at the Karolinska Institutet and Karolinska University Hospital in Sweden. The study showed that the peptide hormone

AnaCardio Receives Regulatory Approval to Start a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK

STOCKHOLM, SWEDEN - 17 November 2022: AnaCardio today announces approval for the GOAL-HF1 Phase 1b/2a study from the competent authorities and ethics committes in Sweden, The Netherlands, Italy and the United Kingdom. This 28-day study will evaluate the effects of orally administered AC01 on safety, tolerability, pharmacokinetics and a series of pharmacodynamic readouts in patients with heart failure with reduced ejection fraction (HFrEF). The study was submitted for approval in EU under the Clinical Trial Regulation (CTR), making it one of the first studies to be approved under the new EU

AnaCardio raises SEK 150 million to advance drug candidate AC01 in heart failure

STOCKHOLM, SWEDEN - 7 September 2022: AnaCardio announced today the completion of a SEK 150 M Series A financing round, co-led by Flerie Invest AB (Flerie) and Industrifonden. 3B Future Health Fund (3BFHF) joined Flerie and Industrifonden to complete the round together with the founding investor Karolinska Development AB and current investors Fredrik and Ann-Helene Ljungström. Founded based on ground-breaking research encompassing pre-clinical and clinical discovery of a novel mode of action in the cardiovascular and heart failure setting by Professor Lars Lund, Professor of Cardiology

AnaCardio exercises option to license a program in heart failure from Helsinn

Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, are pleased to announce that AnaCardio has exercised its option to license from Helsinn a program in heart failure, a condition which is associated with poor quality of life, poor prognosis and which remains a major unmet medical need. Under the

AnaCardio raises SEK 33 million for development of a novel therapy for heart failure

STOCKHOLM, SWEDEN - 3 February 2022: AnaCardio today announced the completion of a fundrasing round of 33 MSEK. The funds will be used to progress clinical development of its lead asset in heart failure. The capital injection is comprised of a convertible loan granted by Karolinska Development AB, LLD Nybohov Invest AB and Fredrik and Ann-Helene Ljungström.   “We are pleased that these prominent investors want to continue supporting AnaCardio on its journey to improve the treatment options for heart failure patients. With this capital injection we are on-track to progress with our

AnaCardio appoints Patrik Strömberg as CEO

STOCKHOLM, SWEDEN - 22 October 2021: AnaCardio AB announces today that Patrik Strömberg has been appointed Chief Executive Officer effective as of September 1, 2021. Patrik Strömberg joins AnaCardio from his previous role as Vice President, External Innovation, Sourcing & Evaluation at Swedish Orphan Biovitrum AB (Sobi). Patrik has extensive experience from the pharmaceutical industry from senior roles in both R&D and Business Development, and he holds a PhD in biochemistry from Karolinska Institutet and an MBA from Stockholm Business School, Stockholm University. "We are very pleased to

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe